A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician’s Choice in a New Therapeutic Scenario

Dipasquale A, Marinello A, Santoro A

Journal of Hepatocellular Carcinoma 2021, 8:241-251

Published Date: 15 April 2021